Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shiromani Jayawardhana

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 3, 2025
A Rapid Method for Purifying Intact Trypanosoma cruzi Amastigotes from Host Cells, In Vitro and In Vivo, for Downstream 'Omic AnalysisFrancisco Olmo, Shiromani Jayawardhana, Richard L Atherton, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2018
Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas DiseaseAmanda Fortes Francisco, Shiromani Jayawardhana, Martin C Taylor, et al.
Cellular Microbiology|February 27, 2016
Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathyMichael D Lewis, Amanda Fortes Francisco, Martin C Taylor, et al.
Parasitology|August 24, 2017
Biological factors that impinge on Chagas disease drug developmentAmanda F Francisco, Shiromani Jayawardhana, Michael D Lewis, et al.
Scientific Reports|July 28, 2018
Imaging the development of chronic Chagas disease after oral transmissionMichael D Lewis, Amanda F Francisco, Shiromani Jayawardhana, et al.
Antimicrobial Agents and Chemotherapy|May 28, 2015
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo ImagingAmanda Fortes Francisco, Michael D Lewis, Shiromani Jayawardhana, et al.
Plos Neglected Tropical Diseases|March 21, 2020
Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infectionMartin C Taylor, Alexander Ward, Francisco Olmo, et al.
Molecules (Basel, Switzerland)|June 21, 2020
Challenges in Chagas Disease Drug DevelopmentAmanda F Francisco, Shiromani Jayawardhana, Francisco Olmo, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2025
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas diseaseShiromani Jayawardhana, Francisco Olmo, Amanda Fortes Francisco, et al.
Plos Pathogens|November 13, 2023
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in miceShiromani Jayawardhana, Alexander I Ward, Amanda F Francisco, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|November 3, 2025
A Rapid Method for Purifying Intact Trypanosoma cruzi Amastigotes from Host Cells, In Vitro and In Vivo, for Downstream 'Omic AnalysisFrancisco Olmo, Shiromani Jayawardhana, Richard L Atherton, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2018
Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas DiseaseAmanda Fortes Francisco, Shiromani Jayawardhana, Martin C Taylor, et al.
Cellular Microbiology|February 27, 2016
Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathyMichael D Lewis, Amanda Fortes Francisco, Martin C Taylor, et al.
Parasitology|August 24, 2017
Biological factors that impinge on Chagas disease drug developmentAmanda F Francisco, Shiromani Jayawardhana, Michael D Lewis, et al.
Scientific Reports|July 28, 2018
Imaging the development of chronic Chagas disease after oral transmissionMichael D Lewis, Amanda F Francisco, Shiromani Jayawardhana, et al.
Antimicrobial Agents and Chemotherapy|May 28, 2015
Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo ImagingAmanda Fortes Francisco, Michael D Lewis, Shiromani Jayawardhana, et al.
Plos Neglected Tropical Diseases|March 21, 2020
Intracellular DNA replication and differentiation of Trypanosoma cruzi is asynchronous within individual host cells in vivo at all stages of infectionMartin C Taylor, Alexander Ward, Francisco Olmo, et al.
Molecules (Basel, Switzerland)|June 21, 2020
Challenges in Chagas Disease Drug DevelopmentAmanda F Francisco, Shiromani Jayawardhana, Francisco Olmo, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2025
Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas diseaseShiromani Jayawardhana, Francisco Olmo, Amanda Fortes Francisco, et al.
Plos Pathogens|November 13, 2023
Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in miceShiromani Jayawardhana, Alexander I Ward, Amanda F Francisco, et al.
Pageof 3